Earnings History Data for Cerevel Therapeutics Holdings, Inc. (CERE) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Inc. treats neuroscience diseases. The company's diversified pipeline comprising clinical-stage investigational therapies and several preclinical compounds to treat neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics Inc., formerly known as Acquisition Corp II, is headquartered in Boston.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01-11-2023 | PM | CERE | Cerevel Therapeutics Holdings, Inc. | 3,660 | -0.61 | -0.63 | -0.66 | Cerevel Therapeutics GAAP EPS of -$0.61 beats by $0.04 [11/1/2023 6:31 AM] |
25.35 | 1.70 (7.19%) |
24.00 | 0.35 (1.48%) |
19.59 - 35.98 | 1,571,169 | 870,000 | 167 | ||
| 02-08-2023 | PM | CERE | Cerevel Therapeutics Holdings, Inc. | 4,800 | -0.63 | -0.65 | -0.61 | Cerevel Therapeutics GAAP EPS of -$0.63 beats by $0.06 [8/2/2023 6:41 AM] |
26.13 | -4.52 (-14.75%) |
0.0 | 0.0 (0.00%) |
22.63 - 41.46 | 2,184,108 | 350,000 | 0 | ||
| 03-05-2023 | PM | 6:30 AM ET (May 3) |
CERE | Cerevel Therapeutics Holdings, Inc. | 4,900 | -0.67 | -0.67 | -0.46 | Cerevel Therapeutics GAAP EPS of -$0.67 in-line [5/3/2023 6:34 AM] |
31.86 | 0.96 (3.12%) |
30.62 | -0.27 (-0.89%) |
19.86 - 41.46 | 1,228,505 | 720,000 | 350 | |
| 22-02-2023 | PM | 6:30 AM ET (Feb 22) |
CERE | Cerevel Therapeutics Holdings, Inc. | 5,100 | -0.59 | -0.64 | -0.40 | Cerevel Therapeutics GAAP EPS of -$0.59 beats by $0.05 [2/22/2023 6:31 AM] |
26.59 | -4.41 (-14.21%) |
0.0 | 0.0 (0.00%) |
19.86 - 41.46 | 2,310,621 | 510,000 | 0 | |
| 08-11-2022 | PM | 6:15 AM ET (Nov 8) |
CERE | Cerevel Therapeutics Holdings, Inc. | 4,430 | -0.66 | -0.62 | -0.43 | Cerevel Therapeutics GAAP EPS of -$0.66 misses by $0.04 [11/8/2022 6:41 AM] |
25.77 | -1.34 (-4.95%) |
27.11 | 0.0 (0.00%) |
19.86 - 46.16 | 710,644 | 510,000 | 14,311 | |
| 01-08-2022 | PM | 6:30 AM ET (Aug 1) |
CERE | Cerevel Therapeutics Holdings, Inc. | 3,960 | -0.61 | -0.50 | -0.42 | Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13 [8/1/2022 6:19 AM] |
27.62 | 1.33 (5.06%) |
26.29 | 0.0 (0.00%) |
19.86 - 46.16 | 342,901 | 470,000 | 14,580 | |
| 10-05-2022 | PM | 6:30 AM ET (May 10) |
CERE | Cerevel Therapeutics Holdings, Inc. | 3,770 | -0.46 | -0.43 | -0.40 | Cerevel Therapeutics GAAP EPS of -$0.46 [5/10/2022 6:34 AM] |
23.02 | 0.84 (3.81%) |
22.18 | 0.0 (0.00%) |
12.01 - 46.16 | 385,612 | 423,171 | 17,165 | |
| 01-03-2022 | PM | 6:30 AM ET (Mar 1) |
CERE | Cerevel Therapeutics Holdings, Inc. | 3,750 | -0.40 | -0.41 | -0.27 | Cerevel Therapeutics GAAP EPS of -$0.40 [3/1/2022 6:33 AM] |
28.30 | 1.83 (6.89%) |
26.47 | 0.0 (0.00%) |
12.01 - 46.16 | 369,272 | 570,000 | 11,527 | |
| 10-11-2021 | PM | 6:30 AM ET (Nov 10) |
CERE | Cerevel Therapeutics Holdings, Inc. | 6,460 | -0.43 | -0.40 | -4.83 | Cerevel Therapeutics reports Q3 results [11/10/2021 6:37 AM] |
38.67 | -4.75 (-10.94%) |
43.42 | 0.0 (0.00%) |
10.33 - 46.16 | 405,771 | 370,000 | 7,718 | |
| 11-08-2021 | PM | 6:30 AM ET (Aug 11) |
CERE | Cerevel Therapeutics Holdings, Inc. | 3,580 | -0.42 | -0.41 | 0.00 | Cerevel Therapeutics reports Q2 results [8/11/2021 10:04 AM] |
25.06 | -0.50 (-1.96%) |
25.95 | 0.39 (1.53%) |
9.00 - 31.09 | 994,590 | 570,000 | 1,972 | |
| 17-05-2021 | PM | 6:30 AM ET (May 17) |
CERE | Cerevel Therapeutics Holdings, Inc. | 1,700 | -0.40 | -0.45 | 0.00 | Cerevel Therapeutics reports Q1 results [5/17/2021 8:09 AM] |
13.50 | -0.10 (-0.74%) |
13.60 | 0.0 (0.00%) |
9.00 - 18.84 | 99,842 | 210,000 | 10,693 | |
| 24-03-2021 | PM | 6:30 AM ET (Mar 24) |
CERE | Cerevel Therapeutics Holdings, Inc. | 2,260 | -0.27 | -0.37 | 0.00 | Cerevel Therapeutics reports Q4 results [3/24/2021 6:37 AM] |
12.20 | -5.39 (-30.64%) |
17.59 | 0.0 (0.00%) |
9.00 - 18.84 | 614,095 | 290,000 | 1,843 | |